First phase I clinical trial of an HIV-1 subtype D gp140 env... : AIDS

Home	Current Issue	Previous Issues	Published Ahead-of-Print	Collections	For Authors	Journal Info

Home > January 2, 2008 - Volume 22 - Issue 1 > First phase I clinical trial of an HIV-1 subtype D gp140 env...

< Previous Abstract | Next Abstract >

Text sizing:

AIDS:

2 January 2008 - Volume 22 - Issue 1 - p 149-151

doi: 10.1097/QAD.0b013e3282f174ed

Research Letters

First phase I clinical trial of an HIV-1 subtype D gp140 envelope protein vaccine: immune activity induced in all study participants

Hurwitz, Julia L^a,b,d; Lockey, Timothy D^a,c; Jones, Bart^a,b; Freiden, Pamela^b; Sealy, Robert^a,b; Coleman, John^c; Howlett, Nanna^b; Branum, Kristen^b; Slobod, Karen S^b,e

Abstract

To combat HIV-1 diversity, we are developing a multienvelope vaccine (comprising DNA, vaccinia virus and protein vectors). Toward this goal, we conducted a phase I clinical trial of EnvPro, a gp140 protein formulated in alum. The vaccine was well tolerated and elicited an immune response in every trial participant.

Username or Email:

Password:

Remember me

Forgot Password?

Article Tools

AIDS

First phase I clinical trial of an HIV-1 subtype D gp140 envelope protein vaccine: immune activity induced in all study participants

Hurwitz, Julia La,b,d; Lockey, Timothy Da,c; Jones, Barta,b; Freiden, Pamelab; Sealy, Roberta,b; Coleman, Johnc; Howlett, Nannab; Branum, Kristenb; Slobod, Karen Sb,e

Abstract

Hurwitz, Julia L^a,b,d; Lockey, Timothy D^a,c; Jones, Bart^a,b; Freiden, Pamela^b; Sealy, Robert^a,b; Coleman, John^c; Howlett, Nanna^b; Branum, Kristen^b; Slobod, Karen S^b,e